Key Summary:
- Cefazolin demonstrated noninferiority for 90-day mortality in MSSA bacteraemia.
- Acute kidney injury occurred in 13.9% versus 19.6% of patients.
- Findings support cefazolin as a potentially safer treatment alternative.

CEFAZOLIN may offer a safer alternative to conventional antistaphylococcal penicillins for treating serious bloodstream infections, according to findings from an international randomised trial published in the New England Journal of Medicine. The antibiotic demonstrated comparable effectiveness in preventing mortality while significantly reducing the incidence of acute kidney injury.
The findings come from the Staphylococcus aureus Network Adaptive Platform (SNAP) trial, which investigated the effectiveness and safety of cefazolin compared with flucloxacillin or cloxacillin in adults with methicillin-susceptible Staphylococcus aureus (MSSA) bacteraemia. These infections are associated with substantial mortality, making the selection of effective and well-tolerated antibiotic treatments particularly important.
The open-label, randomised study was conducted between February 2022 and August 2024 as part of an ongoing international adaptive platform trial. Researchers evaluated all-cause mortality within 90 days as the primary outcome, alongside secondary safety outcomes, including the development of acute kidney injury within 14 days of enrolment.
Among 1,287 patients included in the primary analysis, 90-day mortality was 15.0% (97 of 645 patients) in the cefazolin group, compared with 17.0% (109 of 642 patients) in the antistaphylococcal penicillin group.
The adjusted odds ratio for mortality was 0.81 (95% credible interval: 0.59–1.12), with a 99.2% probability of noninferiority. These findings demonstrated that cefazolin was not meaningfully less effective than flucloxacillin or cloxacillin in preventing death within 90 days. Although the probability of superiority was 89.8%, the results did not establish that cefazolin was superior for survival.
Importantly, cefazolin was associated with a lower incidence of acute kidney injury. Kidney complications occurred in 13.9% (92 of 660 patients) receiving cefazolin, compared with 19.6% (127 of 648 patients) receiving flucloxacillin or cloxacillin.
This represented an absolute difference of 5.7 percentage points, with an adjusted odds ratio of 0.67 (95% credible interval: 0.50–0.89). The probability that cefazolin was superior in reducing acute kidney injury was 99.7%.
These findings are particularly relevant because kidney injury can complicate the management of severe bacterial infections, potentially affecting treatment decisions and increasing the need for additional monitoring.
The study provides randomised evidence supporting cefazolin as an effective alternative to traditional antistaphylococcal penicillins for MSSA bloodstream infections. Its favourable kidney safety profile may offer an important advantage when clinicians are selecting antibiotic regimens, particularly for patients at increased risk of renal complications.
However, the trial was open-label, meaning clinicians and patients were aware of the treatment administered, and the findings should be interpreted within the context of the study population and its eligibility criteria.
Overall, the researchers concluded that cefazolin was noninferior to flucloxacillin or cloxacillin for 90-day mortality and was associated with fewer cases of acute kidney injury. The results may help inform future antibiotic treatment decisions for patients with serious MSSA bloodstream infections.
Reference
Lee T et al. Staphylococcus aureus Network Adaptive Platform (SNAP) Trial Group. Cefazolin for Methicillin-Susceptible Staphylococcus aureus Bacteremia. N Engl J Med. 2026;394(23):2329-39.
Adobe Stock
Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.